INAB
Closed
In8bio inc
2.07
-0.02 (-0.96%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.09
Day's Range: 2.06 - 2.135
Send
sign up or login to leave a comment!
When Written:
1.28
In8bio Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative therapies for the treatment of cancer and other diseases. The company's proprietary platform technology, called Gamma Delta T cell engager, is designed to harness the power of the body's immune system to target and destroy cancer cells. In8bio's pipeline includes several product candidates in various stages of development, including INB-200, which is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. The company was founded in 2016 and is headquartered in New York City.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








